Document is current
Any future updates will be listed below
-
Authors
Takeuchi, Tsutomu https://orcid.org/0000-0003-1111-8218
Chino, Yukihiro https://orcid.org/0000-0001-6484-4673
Kawanishi, Masafumi https://orcid.org/0000-0003-4104-8548
Nakanishi, Megumi
Watase, Hirotaka
Mano, Yoko
Sato, Yuri
Uchida, Saeko
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
-
Funding
Funding for this research was provided by:
Taisho Pharmaceutical Co., Ltd. Tokyo, Japan
- License Information
-
More Information
Article History
Received: 14 November 2022
Accepted: 24 March 2023
First Online: 13 April 2023
Declarations
:
: The protocols of the OHZORA and the NATSUZORA trials were approved by the institutional review board of each testing facility and the trials were conducted in compliance with the Declaration of Helsinki and GCP. Informed consent was obtained from the patients prior to study participation.
: Not applicable.
: TT and YT have received honoraria for lectures and consulting fees from Taisho Pharmaceutical Co., Ltd. YC, MK, MN, HW, YM, YS, and SU are employees of Taisho Pharmaceutical Co., Ltd.
